IRON SUCROSE Drug Patent Profile

When do Iron Sucrose patents expire, and what generic alternatives are available?

Iron Sucrose is a drug marketed by Intl Medication Sys, Mylan Labs Ltd, and Sandoz. and is included in three NDAs.

The generic ingredient in IRON SUCROSE is iron sucrose. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the iron sucrose profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Iron Sucrose

A generic version of IRON SUCROSE was approved as iron sucrose by INTL MEDICATION SYS on August 8^th, 2025.

Summary for IRON SUCROSE

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	3
Clinical Trials:	181
DailyMed Link:	IRON SUCROSE at DailyMed

Recent Clinical Trials for IRON SUCROSE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cheng-Kung University Hospital	PHASE4
University of California, San Diego	PHASE2
Regeneron Pharmaceuticals	PHASE2

See all IRON SUCROSE clinical trials

Pharmacology for IRON SUCROSE

Drug Class	Parenteral Iron Replacement Phosphate Binder
Mechanism of Action	Phosphate Chelating Activity

US Patents and Regulatory Information for IRON SUCROSE

IRON SUCROSE is protected by zero US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Intl Medication Sys	IRON SUCROSE	iron sucrose	INJECTABLE;INTRAVENOUS	208977-001	Aug 8, 2025	AB	RX	No	No
Sandoz	IRON SUCROSE	iron sucrose	INJECTABLE;INTRAVENOUS	212340-001	Aug 8, 2025	AB	RX	No	No
Mylan Labs Ltd	IRON SUCROSE	iron sucrose	INJECTABLE;INTRAVENOUS	212559-001	Aug 8, 2025	AB	RX	No	No
Sandoz	IRON SUCROSE	iron sucrose	INJECTABLE;INTRAVENOUS	212340-002	Aug 8, 2025	AB	RX	No	No

Iron Sucrose Market Dynamics, Patent Status, Competition, and Financial Trajectory

Last updated: September 8, 2026

Iron sucrose is a mature intravenous iron product with broad generic availability, limited remaining patent protection, and durable demand from chronic kidney disease, dialysis, and iron-deficiency anemia. The original branded product, Venofer, has lost most exclusivity in the United States. Commercial value has shifted from patent pricing to manufacturing reliability, hospital contracts, reimbursement, supply continuity, and geographic reach.

The market remains economically relevant because iron sucrose is used in high-volume institutional settings. Its financial trajectory is volume-driven rather than innovation-driven. Generic price pressure limits unit economics, while newer high-dose intravenous irons compete for non-dialysis and hospital use.

What is iron sucrose and how is it used?

Iron sucrose is an intravenous iron-carbohydrate complex used to treat iron-deficiency anemia, particularly in patients with chronic kidney disease. Venofer received U.S. Food and Drug Administration approval in November 2000 under NDA 020955. Its original FDA indication covered iron-deficiency anemia in patients with chronic kidney disease, including patients receiving hemodialysis, peritoneal dialysis, and erythropoietin therapy (U.S. Food and Drug Administration [FDA], 2000).

Iron sucrose is administered intravenously because oral iron is often inadequate, poorly tolerated, or too slow in patients with advanced kidney disease. Dialysis centers remain a core demand channel because patients frequently require repeated iron replacement.

Principal clinical and commercial uses

Use segment	Commercial role
Hemodialysis-associated anemia	Core historical market for Venofer and generics
Peritoneal dialysis	Recurring outpatient use
Non-dialysis chronic kidney disease	Growth opportunity, but faces competition from newer intravenous irons
Hospital iron-deficiency anemia	Used when rapid iron replacement is required
Postpartum and perioperative anemia	Selective use, often competing with newer high-dose products
Oncology and inflammatory disease	Physician-directed use, subject to underlying disease and reimbursement

The product requires intravenous administration and clinical monitoring. That limits retail pharmacy substitution and gives hospitals, dialysis providers, specialty pharmacies, and group purchasing organizations significant purchasing power.

When did iron sucrose lose exclusivity?

The core U.S. exclusivity for iron sucrose ended years ago. Venofer is no longer protected by a commercially meaningful basic patent barrier in the United States.

Milestone	Date or status
Venofer U.S. approval	November 2000
Original branded exclusivity period	Expired
Generic iron sucrose availability	Established in the U.S. market
Current market structure	Originator plus multiple generic suppliers
Biosimilar exclusivity	Not applicable
Primary competitive issue	Price, supply, contracting, and formulation differentiation

Venofer’s market protection was weakened by the nature of the product itself. Iron sucrose is a non-biological iron complex, not a conventional single-molecule drug and not a biologic subject to the biosimilar pathway. FDA-approved competitors have generally entered through abbreviated or hybrid regulatory routes applicable to injectable iron complexes rather than through a biosimilar application.

What patents protect iron sucrose and Venofer?

The original Venofer patent estate is no longer a major U.S. entry barrier. Historical protection focused on iron sucrose compositions, iron-carbohydrate complexes, and manufacturing processes. Patent terms for the original product have expired or become commercially immaterial in the United States.

Patent categories historically associated with iron sucrose

1. Composition patents covering iron sucrose or related iron-sugar complexes.
2. Process patents covering manufacture, purification, molecular-weight control, and stability.
3. Formulation patents covering injectable concentrations, excipients, containers, and storage.
4. Method-of-use patents covering treatment of anemia in chronic kidney disease or dialysis populations.

The current commercial position is different from the historical patent position. Even when composition patents expire, injectable iron products can retain operational barriers because manufacturers must consistently control particle size, iron release, sucrose content, impurities, sterility, and stability.

Are formulation patents still important?

Formulation patents are less important than manufacturing controls for standard iron sucrose injection in the United States. The product is generally sold as a sterile aqueous injection in single-dose vials or ampules. Generic suppliers compete primarily on equivalent product quality, regulatory approval, supply reliability, and price.

A formulation patent could still matter for a differentiated presentation, such as a novel concentration, container, administration method, or combination product. Those rights would not normally prevent sale of standard generic iron sucrose unless they were listed and enforceable against the specific generic product.

What is the Orange Book status of Venofer?

Venofer is listed in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, under NDA 020955. Generic iron sucrose products have entered the U.S. market with therapeutic-equivalence designations where applicable.

The practical Orange Book conclusion is that Venofer does not have a current, unexpired patent listing that creates the type of market barrier associated with newer branded drugs. The product’s economic protection is therefore based on brand preference, contracting, quality history, and channel relationships rather than patent exclusivity (FDA, 2024a).

What does Orange Book status mean for generic entry?

For a generic applicant, the principal risks are regulatory and commercial:

• Demonstrating pharmaceutical equivalence and bioequivalence or the applicable injectable-product standard.
• Establishing consistent iron-sucrose complex characteristics.
• Meeting current good manufacturing practice requirements.
• Securing reliable sterile manufacturing capacity.
• Obtaining hospital, dialysis-provider, and government contracts.
• Managing price erosion after multiple entrants.

Patent litigation risk is materially lower than for a currently patent-protected small-molecule product.

Are there Paragraph IV challenges to Venofer?

Paragraph IV litigation is no longer the central market issue for Venofer. Generic iron sucrose entered after the main patent barriers had weakened, and the product has operated for years in a multi-supplier market.

A Paragraph IV certification can still arise when a generic applicant challenges a listed patent. The certification itself does not guarantee litigation or a 30-month stay. For Venofer, the commercial significance of any new Paragraph IV dispute would depend on whether the challenged patent covered a real product barrier or only a narrow formulation or use.

The market has no widely recognized active patent dispute comparable to high-value litigation involving recently launched specialty drugs. Generic competition is established, and a new patent case would have to overcome the product’s mature regulatory and commercial position.

Which companies compete in the iron sucrose market?

The competitive landscape includes the Venofer originator business, generic injectable manufacturers, and alternative intravenous iron products.

Iron sucrose suppliers and competitors

Company or product	Position
Venofer	Original branded iron sucrose product
American Regent	U.S. Venofer marketing and supply participant
Fresenius Kabi	Generic and hospital injectable supplier; major dialysis channel presence
Hikma	Generic injectable competitor in selected markets
Sagent Pharmaceuticals	Historical generic injectable participant
Teva	Generic pharmaceutical supplier with injectable iron participation in certain markets
Pharmacosmos	Manufacturer of Monoferric and other iron products; competes mainly through newer formulations
CSL Vifor	Global iron franchise owner associated with Venofer and newer iron products
Daiichi Sankyo	U.S. supplier of Injectafer, a competing high-dose intravenous iron
AMAG Pharmaceuticals / subsequent owners	Associated with Feraheme, a competing intravenous iron product

Supplier participation varies by country, approval status, and time. The U.S. market is more fragmented than the originator market was before generic entry.

How does iron sucrose compare with newer intravenous iron products?

Iron sucrose has a lower per-dose iron payload than several newer products. Patients often require multiple administrations, while ferric carboxymaltose, ferric derisomaltose, and ferumoxytol can deliver larger doses in fewer visits.

Product	Active iron complex	Typical commercial positioning
Venofer and generic iron sucrose	Iron sucrose	Established, lower-cost, repeated-dose treatment
Ferrlecit	Sodium ferric gluconate complex	Dialysis and chronic kidney disease market
Injectafer	Ferric carboxymaltose	High-dose iron replacement, outpatient and non-dialysis use
Feraheme	Ferumoxytol	Larger-dose administration, chronic kidney disease and iron-deficiency anemia
Monoferric	Ferric derisomaltose	High-dose replacement with fewer administrations
INFeD	Iron dextran	Older product with broader historical dosing flexibility

How strong is the patent estate for iron sucrose compared with newer products?

Iron sucrose has a weak current patent estate because its principal protection is expired and generic competition is entrenched. Newer products generally have stronger commercial patent positions, especially where patents cover formulations, administration regimens, manufacturing processes, or specific clinical uses.

That advantage is temporary. High-value intravenous iron products also face eventual patent expiry and may encounter reimbursement pressure before generic entry. Their near-term value comes from reduced dosing frequency, physician familiarity, clinical positioning, and remaining exclusivity.

What is the FDA regulatory status of iron sucrose?

Iron sucrose is an FDA-approved injectable prescription product. The reference product is Venofer, NDA 020955. Multiple generic products have received FDA approval through abbreviated or related regulatory pathways.

The principal FDA issues are not basic efficacy questions. They are product quality and equivalence questions, including:

• Complex iron-carbohydrate characterization.
• Batch-to-batch consistency.
• Free iron and iron-release behavior.
• Sterility and particulate control.
• Stability during storage and administration.
• Labeling and dosing consistency.
• Manufacturing-site inspection history.

Iron sucrose illustrates the regulatory difficulty of complex generics. A product may have a straightforward active ingredient description while requiring sophisticated controls to reproduce the reference product’s clinically relevant properties.

What manufacturing and intellectual-property barriers remain?

The key barriers are technical rather than patent-based. Injectable iron products require specialized sterile manufacturing and complex analytical testing. A supplier must produce large commercial batches without unacceptable variability in iron release, molecular-weight distribution, impurities, or particulate content.

Remaining barriers to entry

Barrier	Market effect
Sterile injectable capacity	Limits the number of dependable suppliers
Complex analytical characterization	Raises development and validation costs
Raw-material quality	Affects batch consistency and release testing
Regulatory inspections	Can disrupt supply after warning letters or manufacturing findings
Hospital qualification	Slows switching to new suppliers
Contracting requirements	Favors companies with scale and distribution
Supply-chain resilience	Creates value for dual-source and multi-source procurement

These barriers do not restore patent-like pricing. They can, however, protect established suppliers from rapid displacement and create temporary shortages when a major manufacturer exits or experiences a production interruption.

What is the financial trajectory for iron sucrose?

Iron sucrose has moved through four commercial stages:

1. Originator expansion after Venofer approval.
2. Broad adoption in dialysis and chronic kidney disease.
3. Generic entry and rapid price erosion.
4. Mature, volume-based competition with substitution by high-dose intravenous irons.

The product’s revenue trajectory is therefore structurally different from that of a protected specialty drug. Unit prices decline as generic participation increases, while total market value depends on treatment volume, dialysis prevalence, diagnosis rates, and reimbursement.

Revenue exposure by company type

Company type	Financial exposure
Originator owner	Lower price realization, retained brand and contract revenue
Generic injectable manufacturer	Low-to-moderate margin, dependent on scale and supply reliability
Dialysis-focused supplier	High recurring volume but concentrated customer base
Newer intravenous iron manufacturer	Higher unit economics, exposed to patent and reimbursement risk
Hospitals and dialysis providers	Purchase-cost savings offset by administration and inventory requirements

Public companies generally do not report iron sucrose revenue as a separate line item. Revenue is often combined with broader iron products, hospital injectables, nephrology medicines, or specialty pharmaceuticals. CSL’s acquisition of Vifor Pharma expanded its iron portfolio, but public reporting has not generally isolated Venofer sales from the broader portfolio (CSL Limited, 2022).

What drives future market growth?

Volume growth is likely to come from:

• Rising prevalence of chronic kidney disease.
• Increased recognition and treatment of iron deficiency.
• Expansion of intravenous treatment in non-dialysis patients.
• Hospital use where oral therapy is inadequate.
• Growth in emerging markets with expanding dialysis capacity.

Offsetting forces include:

• Generic price compression.
• Greater use of single- or two-dose high-dose iron products.
• Reimbursement pressure from payers and dialysis providers.
• Oral iron treatment for less severe cases.
• Product shortages or manufacturing interruptions.

The financial outlook is stable but mature. Iron sucrose is unlikely to generate originator-style growth without a new formulation, expanded indication, or channel-specific commercial strategy.

What generic launch scenarios exist for iron sucrose?

Base case: continued multi-source generic supply

The most likely scenario is continued competition among several approved suppliers. Prices remain pressured, while supply contracts favor manufacturers with dependable sterile capacity and national distribution.

Upside case: volume expansion

Demand could grow if intravenous iron use increases in non-dialysis chronic kidney disease, postpartum anemia, or hospital outpatient treatment. Volume growth would not necessarily translate into equivalent revenue growth because generic pricing remains constrained.

Downside case: substitution by high-dose products

Newer products could take share where fewer administrations reduce total treatment cost or improve patient convenience. This is most relevant outside the traditional dialysis market.

Disruption case: supplier exit or shortage

The market can tighten if a major sterile injectable supplier leaves, faces regulatory action, or experiences manufacturing disruption. Shortages may increase near-term pricing and improve utilization of remaining suppliers, but they do not create durable exclusivity.

What litigation and settlement agreements affect iron sucrose?

No major active U.S. litigation or settlement is broadly recognized as controlling the current commercial iron sucrose market. Historical disputes were more relevant during the transition from branded Venofer to generic products. The current market is primarily governed by FDA approvals, supply contracts, reimbursement policy, and manufacturing compliance.

Settlement value is limited because the basic product has been generic for years. A new settlement would matter only if it involved a narrow formulation, a delivery system, a manufacturing process, or a market-specific exclusivity arrangement.

What geographic markets are most important?

The United States is a major value market because of its large dialysis population, institutional purchasing, and established reimbursement mechanisms. Europe has strong intravenous iron use but more intense price and tender pressure. Emerging markets offer volume growth as dialysis infrastructure expands, although local pricing and regulatory requirements can reduce margins.

Region	Market characteristics
United States	Mature generic market, significant dialysis demand, hospital contracting
Europe	Tender-driven purchasing and strong use of intravenous iron
Japan	Local regulatory and supply requirements; established nephrology use
China	Growing dialysis population and domestic manufacturing competition
India	Large volume potential, lower pricing, broad generic competition
Latin America	Variable access, public procurement, and import dependence
Middle East and Africa	Growth linked to hospital infrastructure and dialysis expansion

Geographic patent risk is limited for the original product, but local registration, manufacturing standards, data requirements, and procurement rules remain commercially decisive.

Key Takeaways

• Iron sucrose is a mature intravenous iron product with established generic competition.
• Venofer’s principal U.S. patent protection has expired and does not create a meaningful current entry barrier.
• The product is approved by the FDA under NDA 020955 and remains commercially important in chronic kidney disease and dialysis.
• The market’s main barriers are sterile manufacturing, complex product characterization, regulatory compliance, and supply reliability.
• Generic entry has reduced prices and shifted competition toward contracts, volume, and dependable supply.
• Newer products such as Injectafer, Feraheme, and Monoferric compete through larger iron doses and fewer administrations.
• Biosimilar risk is not applicable because iron sucrose is a non-biological complex injectable.
• Public companies generally do not disclose iron sucrose revenue separately, limiting product-level financial analysis.
• Long-term market value is likely to remain stable in volume but constrained in price.
• The main commercial risk is substitution by high-dose intravenous irons, not patent litigation.

FAQs

Is iron sucrose still commercially profitable?

Yes, but profitability depends on manufacturing scale, hospital and dialysis contracts, production reliability, and procurement efficiency. Generic unit margins are lower than originator margins.

Does Venofer still have market exclusivity?

Venofer retains brand recognition and commercial relationships, but it does not have meaningful current U.S. patent exclusivity against generic iron sucrose.

Is iron sucrose a biosimilar?

No. Iron sucrose is a complex non-biological iron-carbohydrate injectable. Competitors do not enter through the biosimilar pathway.

Which intravenous iron has the strongest competitive position?

The answer depends on the treatment setting. Iron sucrose remains strong in dialysis because of familiarity and cost. Ferric carboxymaltose, ferumoxytol, and ferric derisomaltose are stronger in settings where high-dose administration and fewer visits matter.

Could iron sucrose prices rise again?

Prices could rise temporarily during shortages or supplier exits. A sustained return to originator-level pricing is unlikely without a major supply disruption or a differentiated protected formulation.

References

CSL Limited. (2022). Annual report 2022. https://www.csl.com/investors

U.S. Food and Drug Administration. (2000). Venofer prescribing information, NDA 020955. https://www.accessdata.fda.gov

U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

U.S. Food and Drug Administration. (2024b). Generic drug user fee amendments and complex drug products. https://www.fda.gov/drugs/generic-drugs

U.S. Renal Data System. (2023). 2023 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases. https://usrds-adr.niddk.nih.gov/2023